Next Article in Journal
Molecular Oxygen Activation by Citric Acid Boosted Pyrite–Photo–Fenton Process for Degradation of PPCPs in Water
Next Article in Special Issue
Absolute Stereochemistry Determination of Bioactive Marine-Derived Cyclopeptides by Liquid Chromatography Methods: An Update Review (2018–2022)
Previous Article in Journal
Almond [Prunus dulcis (Mill.) DA Webb] Processing Residual Hull as a New Source of Bioactive Compounds: Phytochemical Composition, Radical Scavenging and Antimicrobial Activities of Extracts from Italian Cultivars (‘Tuono’, ‘Pizzuta’, ‘Romana’)
Previous Article in Special Issue
Positional Distribution of Fatty Acids in Processed Chinook Salmon Roe Lipids Determined by 13C Magnetic Resonance Spectroscopy (NMR)
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 2
10.3390/molecules28020606
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antifungal Potential of Marine Organisms of the Yucatan Peninsula (Mexico) against Medically Important Candida spp.

by
Dawrin Pech-Puch
1,2,
Diana Grilo
3,
Susana Eunice Calva-Pérez
1,
Andreia Pedras
3,
Harold Villegas-Hernández
1,
Sergio Guillén-Hernández
1,
Raúl Díaz-Gamboa
1,
Mateo Forero Tunjano
4,
Jaime Rodríguez
4,
Oscar A. Lenis-Rojas
3,*,
Carlos Jiménez
4,* and
Catarina Pimentel
3,*
1
Departamento de Biología Marina, Universidad Autónoma de Yucatán, Km. 15.5, Carretera Mérida-Xmatkuil, A.P. 4-116 Itzimná, Merida CP 97100, Mexico
2
Escuela Nacional de Estudios Superiores Unidad Mérida (ENES Mérida), Universidad Nacional Autónoma de México (UNAM), Carretera Mérida-Tetiz km 4.5, Tablaje, Catastral No. 6998, Municipio de Ucú, Ucú CP 97357, Mexico
3
Instituto de Tecnologia Química e Biológica António Xavier (ITQB NOVA), Universidade Nova de Lisboa, Oeiras, 1070-312 Lisbon, Portugal
4
Centro de Interdisciplinar de Química e Bioloxía (CICA), Facultade de Ciencias, Universidade da Coruña, 15071 Coruña, Spain
*
Authors to whom correspondence should be addressed.
Molecules 2023, 28(2), 606; https://doi.org/10.3390/molecules28020606
Submission received: 8 November 2022 / Revised: 3 December 2022 / Accepted: 27 December 2022 / Published: 6 January 2023
(This article belongs to the Special Issue Innovative Marine Molecules: Chemistry, Biology and Analysis)
Browse Figures
Versions Notes

Abstract

:
Invasive fungal infections represent a global health threat. They are associated with high mortality and morbidity rates, partly due to the ineffectiveness of the available antifungal agents. The rampant increase in infections recalcitrant to the current antifungals has worsened this scenario and made the discovery of new and more effective antifungals a pressing health issue. In this study, 65 extracts from marine organisms of the Yucatan Peninsula, Mexico, were screened for antifungal activity against Candida albicans and Candida glabrata, two of the most prevalent fungal species that cause nosocomial invasive fungal infections worldwide. A total of 51 sponges, 13 ascidians and 1 gorgonian were collected from the coral reef and mangrove forest in the Yucatan Peninsula (Mexico) and extracted with organic solvents. Nine crude extracts showed potent antifungal activity, of which four extracts from the sponge species Aiolochroia crassa, Amphimedon compressa, Monanchora arbuscula and Agelas citrina had promising activity against Candida spp. Bioassay-guided fractionation of the M. arbuscula extract revealed the remarkable fungicidal activity of some fractions. Analysis of the chemical composition of one of the most active fractions by UHPLC-HRMS and NMR indicated the presence of mirabilin B and penaresidin B, and their contribution to the observed antifungal activity is discussed. Overall, this work highlights marine organisms of the Yucatan Peninsula as important reservoirs of natural products with promising fungicidal activity, which may greatly advance the treatment of invasive fungal infections, especially those afflicting immunosuppressed patients.

1. Introduction

Fungi are important components of most ecosystems on Earth [1]. They are also part of the human microbiota and, under particular circumstances, can cause health-threatening invasive infections, in which the fungus reaches the bloodstream or any major internal organs [2]. The yeast Candida spp. asymptomatically colonizes the skin, mucosal surfaces and the gastrointestinal tract of most healthy individuals [3]. However, some aggressive drug therapies or immunosuppressive infections may promote their transition from commensals to pathogens [4]. As a result, invasive fungal infections caused by commensal Candida spp. are the most prevalent severe fungal infections among hospitalized patients [4,5]. The mortality rates of patients with invasive candidiasis are unacceptably high, even for those who receive timely antifungal therapy [6]. The disease is also associated with high healthcare costs and prolonged hospital stays [7].
Candida albicans is the most frequent causative agent of nosocomial invasive fungal infections [5], followed by Candida glabrata and Candida parapsilosis [8]. C. glabrata has recently emerged as an important pathogen, due to its inherent tolerance to the most prescribed antifungal worldwide—fluconazole—and the rampant increase in clinical isolates that are resistant to the available drugs [9].
Only the following three primary classes of antifungal agents are currently available to treat invasive fungal infections: polyenes, azoles, and echinocandins [10] (Figure 1). The recent emergence of fungi resistant to one or more classes of antifungals has compromised the effectiveness of treatment, and significantly reduced the repertoire of antifungal agents that clinicians have to fight serious fungal infections [11]. This concerning situation has led the WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) to conclude that tackling Candida spp. antifungal resistance should be considered a priority [12]. Clearly, there is an urgent need to develop alternative antifungals that are capable of bypassing the known mechanisms of drug resistance.
The large size and biological diversity of the oceans make them promising natural sources of bioactive molecules [13]. In the marine environment, organisms subjected to a plethora of stimuli produce molecules with unique structural, chemical, and biological characteristics. These marine natural products (MNPs) are a rich source of potential alternative drugs [14], many of which have already entered clinical phase trials [13].
Mexico has been considered as one of the three areas in the world with the greatest terrestrial and marine biodiversity. In particular, the Gulf of Mexico and the Caribbean Sea, which meet in the Yucatan channel, constitute two outstanding marine ecosystems [15]. The single geographical location of the Yucatan channel promotes the abundance of highly diverse and unique marine species, which represent a potential source of bioactive compounds [15,16,17,18].
The antifungal potential of the marine organisms of the Yucatan Peninsula (YP) has not been intensively investigated [15]. The macroalgae are the only group of marine organisms in the YP that have been searched for antifungal activity. Indeed, as far as we know, there are only two reports on this topic. The first, by Morales et al. [19], evaluated the antifungal activity present in the extracts of marine macroalgae against Trichophyton mentagrophytes. In the second, the antifungal activity of marine macroalgae extracts on Pseudocercospora fijiensis, Colletotrichum gloeosporioides and Fusarium oxysporum was tested [20].
In this work, we report the promising antifungal activity of 65 extracts from several marine invertebrate species of the YP against yeast species that cause life-threatening infections.

2. Results and Discussion

2.1. Screening of a Library of Marine Extracts from the Yucatan Peninsula for Antifungal Activity

A library of 65 extracts (51 sponges, 13 ascidians and 1 gorgonian), collected from the coral reef and mangrove forest in the Yucatan Peninsula in Mexico, was screened for antifungal activity against C. albicans and C. glabrata. The crude extracts were resuspended in the smallest possible volume of DMSO, yielding the stock concentrations listed in Table 1. To ensure total solubilization, all the extracts were sonicated prior to use. Next, 5 µL of each extract (Table 1) was added to the wells of a 96-well plate, containing a cellular suspension of C. glabrata or C. albicans. Growth was recorded after 48 h at 30 °C (C. albicans) or 37 °C (C. glabrata), by measuring OD600. Growth ratios were determined in comparison to the control cells and those below 0.5 were considered to be active extracts.
For the concentrations tested (Table 1), 9 of the 65 extracts, obtained from 8 sponge species, showed antifungal activity against C. glabrata (Figure 2). The active extracts were from Aiolochroia crassa (collected from two different locations: Mahahual in the Quintana Roo state (MA18-4) and Alacranes Reef in the Yucatan state (E50)), Amphimedon compressa, Monanchora arbuscula, Leucetta floridana, Agelas sceptrum, A. citrina, A. dilatata, and Haliclona (Rhizoniera) curacaoensis. Four of these extracts (A. crassa (MA18-4), A. compressa (E29), M. arbuscula (E35) and A. citrina (CZE56)) also had antifungal activity against C. albicans (Figure 3). To the best of our knowledge, there are no previous studies on the antifungal activity of the following three sponges: H. (Rhizoniera) curacaoensis, A. crassa, and A. dilatata.
The antifungal activity displayed by the A. citrina extract may be due to the presence of agelasidines (Table 10, Figure 10). It has been reported that the alkaloid (–)-agelasidine C shows strong antifungal activity on C. albicans [21]. Moreover, (–)-agelasidine C and agelasidines E and F, isolated from A. citrina, also showed activity against C. albicans [21,22].
As for A. compressa, methanol extracts obtained from this species have already demonstrated antifungal activity against C. albicans [23]. Accordingly, 8,8′-dienecyclostellettamine (Table 1) isolated from this species is active against C. glabrata and C. albicans [24].
Organic extracts from A. sceptrum (E26-2) were also strongly active against C. glabrata, but less active against C. albicans (Figure 2 and Figure 3, respectively). A compound with antifungal activity against C. albicans and Alternaria sp. known as sceptrin was previously isolated from this species [25].
L. floridana-derived extracts are known to display antifungal activity on C. albicans [26]. In this study, we found that L. floridana crude extracts are very active against C. glabrata (Figure 2).
Batzelladine L, batzelladine D, norbatzelladine L, and ptilomycalin A were isolated from M. arbuscula with high antifungal activity against clinically important fungi. Batzelladin L is active against the filamentous fungus Aspergillus flavus [27], batzelladines D and norbatzelladine L are active against Saccharomyces cerevisiae, a yeast that is phylogenetically close to C. glabrata [28], and the alkaloid ptilomycalin A is active against the yeast Cryptococcus neoformans [29].
We determined the minimum inhibitory concentration (MIC) of the four most active extracts against both Candida spp. (Table 2). The extracts were serial diluted in DMSO and 5 µL was added to the wells of a 96-well plate, containing cellular suspensions of C. glabrata or C. albicans. Growth was recorded after 24 and 48 h at 30 °C (C. albicans) or 37 °C (C. glabrata), by measuring OD600. The MIC was defined as the drug concentration where the relative OD600 fell at least 50% below the control (DMSO alone).
M. arbuscula (E35) was the most active extract against both Candida spp. with an MIC of 3.91 μg/mL (Table 2). The extract of A. compressa was more active against C. glabrata than against C. albicans and the opposite was observed for the extract of A. citrina. The A. crassa extract was the least active against both species. The MIC for A. compressa, M. arbuscula, and A. citrina did not change between 24 and 48 h.
The potent activity of the crude extract from M. arbuscula (E35) on C. albicans and C. glabrata led us to further explore this extract.

2.2. Bioassay-Guided Fractionation of the M. arbuscula Extract

The M. arbuscula crude extract was partitioned using the modified Kupchan procedure to obtain the following five fractions: E35-WF, E35-BF, E35-HF, E35-WMF, and E35-DF (Table 3). The three most active fractions against both C. glabrata and C. albicans were E35-DF, E35-BF, and E35-WMF (Table 3, Figure 4 and Figure 5), with E35-DF being the most active fraction.
The fraction E35-DF, which required the slightest amount to produce a significant impact on yeast growth (Table 3), was then subjected to solid phase extraction (SPE) using an RP-18 cartridge. The procedure generated seven sub-fractions, R1–R7 (Table 4), whose fungistatic and fungicidal activity were evaluated on C. glabrata and C. albicans.
We found that all the sub-fractions were active against C. glabrata and C. albicans, with the sub-fractions R2, R3, R4 and R5 exceling in terms of antifungal efficacy at the concentrations assayed (Figure 6 and Table 5).
The MICs of the most active sub-fractions (R2 to R5) were determined next (Table 5). With the exception of sub-fraction R4, all the other sub-fractions had lower MICs than the original E35-FD fraction (Table 5), confirming the success of the fractionation step.
In addition to C. albicans and C. glabrata, other Candida spp. are emerging as important pathogens. Among them are C. krusei, C. tropicalis, and C. parapsilosis, which together with the former are responsible for more than 90 percent of all yeast infections [30]. Therefore, the most active fractions R2–R5 were also tested against C. krusei, C. tropicalis, and C. parapsilosis (Table 6).
All of the sub-fractions showed activity against C. krusei, C. tropicalis, and C. parapsilosis, with sub-fraction R4 being the most active one.
By determining the minimum fungicidal concentration (MFC), we also found that sub-fractions R4 and R5 generally had the highest fungicidal activity (lower MFCs) against all species at 24 and 48 h (at concentrations that were two to eight times higher than the MIC). The exception was C. parapsilosis, for which the sub-fractions R2 and R3 had the strongest activity at 48 h (Table 7).

2.3. De-Replication Analysis of the Sub-Fractions from M. arbuscula

As a first attempt to identify the compounds responsible for the promising antifungal activity of sub-fractions R2, R3, R4 and R5, de-replication analyses of these fractions were carried out using the UHPLC-HRMS positive mode (see Supplementary Materials for R2, R3, and R5 UHPLC-HRMS experiment; Figures S1–S3 and Figure 7 for R4). The [M + H]+ ion adducts that corresponded to all the signals detected in the LC/MS chromatograms were analyzed using the Antimarin® and Scifinder® platforms.
A total of 19 [M + H]+ ion adducts that corresponded to 19 UHPLC signals were detected, including 3 for R2, 2 for R3, 7 for R4, and 7 for R5 (Table 8).
Two compounds that corresponded to the [M + H]+ ion adducts found in the R4 sub-fraction were identified as mirabilin B and penaresidin B (Figure 8). The HRMS of the compounds eluted with a retention time of 9.12 min showed an [M + H]+ ion adduct at m/z 246.1965, matching that of mirabilin B [33] (calculated as m/z 246.1964, Figure 7B). The other match, with a retention time of 11.00 min and an experimental value of [M + H]+ m/z 330.3001, corresponded to penaresidin B [31,32] (calculated as m/z 330.3002, Figure 7C, Figures S5 and S7). The remaining [M + H]+ ion adducts could not be identified; therefore, they may be either compounds not yet included in the Antimarin® and Scifinder® platforms or new compounds.
To confirm the presence of mirabilin B (1) and penaresidin B (2) (Figure 8) in the R4 sub-fraction, the carbon chemical shift signals of the 13C NMR spectrum of this sub-fraction (see Supplementary Materials, Figures S4 and S6) were compared to those reported for these compounds in the literature, using a Pearson’s chi-squared goodness of fit test ( χ 2 ) with Yates continuity correction (Table 9). The 13C NMR spectrum of the R4 sub-fraction indicated the presence of the main carbon chemical shifts of compounds 1 and 2.
The chi-squared goodness of fit test revealed that the experimental values for compound (1) did not differ significantly, at a 99% confidence level, from the reported values ( χ Y 2 = 0.0460 ; p-value = 0.8302). The same was observed for compound (2) ( χ Y 2 = 0.0405 ; p-value = 0.8405). Thus, we conclude that the experimental data do not differ significantly from those expected for both compounds.
Mirabilin B was identified in M. arbuscula (previously known as Monanchora unguifera) and demonstrated activity against Cryptococcus neoformans [34], but there are no data on its activity against Candida spp. Penaresidin B, isolated from the marine sponge Penares sp., has no antifungal activity against C. neoformans, Aspergillus niger, or C. albicans [35]. Although at this stage, we cannot rule out the contribution of the other compounds (Table 8), it may well be that the antifungal activity observed in R4 results from mirabilin B or from its synergetic interaction with those unidentified NPs.

3. Materials and Methods

3.1. General Experimental Procedures

The separation was performed using a Waters XBridge column C18, 2.1 × 150 mm, 3.5 µm particle size, P/N 186003023 (Optima™ LC/MS Grade, Thermo Fisher Scientific, Waltham, MA, USA). The column temperature was maintained at 30 °C. The data were acquired on Q Exactive Focus (Thermo Fisher Scientific, Waltham, MA, USA) coupled to UHPLC, using Xcalibur software v.4.0.27.19 (Thermo Fisher Scientific, Waltham, MA, USA). The method consisted of several cycles of full MS scans (R = 70,000) in positive mode and negative mode in separate runs. External calibration was performed using the LTQ VELOS ESI Positive Ion Calibration Solution (ref.: 11340360, Thermo Fisher Scientific, Waltham, MA, USA) and Negative Ion Calibration Solution (ref.: 11360360, Thermo Fisher Scientific, Waltham, MA, USA). The raw MS was analyzed using Compound Discoverer software v2.1 (Thermo Fisher Scientific, Waltham, MA, USA).
13C NMR spectra were recorded on a Bruker Avance 500 spectrometer at 125 MHz, using CDCl3. The chromatographic analysis was performed on an UltiMate 3000 UHPLC (Thermo Fisher Scientific, Waltham, MA, USA).

3.2. Statistical Analyses

A Pearson’s chi-squared goodness of fit test ( χ 2 ) was applied to determine whether our data (experimental chemical shift values of 13C NMR for compound (1)) were significantly different from those expected (reported chemical shift values of 13C NMR for compound 1). The same procedure was carried out for compound (2). It is worth mentioning that both χ 2 tests were applied with the Yates continuity correction to reduce the approximation error, and thus prevent overestimation of the statistical significance for small data [36]. Herein, the chi-squared statistic was as follows:
χ Y 2 = ∑ i = 1 n O i − E i − 0.5 2 E i
where O i would represent the observed values, and E i would be the expected values.

3.3. Animal Collection and Identification

Samples of animals were collected by snorkeling and scuba diving in different coastal zones of the Yucatan Peninsula, Mexico, during the following three different periods: September–December 2016, January–March 2017, and September 2018. The selected species were collected from the following two different regions: Mexican Caribbean (Cozumel Island, Rio Indio, Mahahual, and Bermejo, Quintana Roo) and Campeche Bank (Alacranes Reef and Progreso, Yucatan) (Figure 9).
The sponges were identified at the ICMyL-UNAM (Mexico), while the ascidians were identified at the University of Vigo (Spain) and Autonomous University of Yucatan (Mexico). Taxonomic information, collection sites, and previous reports on the antifungal activity of the species/genus of the 65 marine organisms are shown in Table 10. The structures of the compounds with antifungal activity previously isolated from marine species, whose extracts were tested in this work, are depicted in Figure 10.

3.4. Preparation of the Organic Extracts

Tissue slices of each species were exhaustively extracted three times in a lapse of 24 h each, with a 500 mL mixture of dichloromethane–methanol (1:1), at 25 °C. The solvent was filtered and then removed under vacuum at 40 °C with a rotatory evaporator. The extracts were stored at −20 °C in tightly sealed glass vials.

3.5. Antifungal Assays

3.5.1. Screening of the Marine Extracts

C. glabrata (ATCC2001) and C. albicans (SC5314) were maintained in yeast peptone dextrose (YPD) agar plates and grown at 37 °C or 30 °C, respectively. Crude extracts were dissolved in DMSO, and 5 µL was added to the wells of a 96-well plate, containing 95 µL of RPMI-1640 medium at pH 7. Extract concentrations ranged from 125 to 12.5 µg/mL (Table 1). Cellular suspensions of C. glabrata or C. albicans (3 × 103 CFU/mL) were prepared from fresh cultures grown overnight on YPD agar plates, and 100 µL was added to each well. Growth in RPMI-1640 medium was recorded after 48 h, by measuring OD600. The growth condition without an extract/fraction but with DMSO (control condition, 2.5% DMSO) was used as the normalization condition, after background (RPMI-1640 medium) subtraction. Growth ratios below 0.5 were considered for further analyses.

3.5.2. Antifungal Susceptibility Testing

The minimal inhibitory concentration (MIC) of C. glabrata and C. albicans was determined by conducting broth microdilution assays in accordance to the CLSI (Clinical Laboratory and Standards Institute) standard method (M27-A3) [74], with few modifications. Growth in RPMI-1640 medium was recorded after 24 and 48 h at 30 °C (C. albicans) or 37 °C (C. glabrata), by measuring OD600. The growth condition without an extract/(sub-)fraction, but with DMSO (final concentration 2.5%), was used as the normalization condition, after background (RPMI-1640 medium) subtraction. The MIC was set as the lowest extract/(sub-)fraction concentration at which there was a ≥50% decrease in growth compared to the control (cells grown in the presence of 2.5% of DMSO). At least, three independent assays were performed for each crude extract/fraction. Fluconazole (ACROS Organics) was used as a reference antifungal. The range of tested concentrations for each extract/(sub-)fraction is listed in Table S1. The minimal fungicidal concentration (MFC) was assessed by spotting 5 μL of the above cultures onto YPD agar plates. Growth was recorded after 24 or 48 h at 30 °C (C. albicans) or 37 °C (C. glabrata). The MFC corresponds to the concentration of the fraction that decreases the number of cells compared to the initial inoculum.

3.6. Bioassay-Guided Fractionation of the M. arbuscula Crude Extract

Sliced bodies of M. arbuscula (wet weight, 29.8 g; dry weight, 15.3 g) were exhaustively extracted, as previously described, to obtain 1.70 g of a crude residue. Liquid–liquid fractionation of 1.65 g of crude extract with H2O/CH2Cl2 (1:1 v/v) produced an aqueous and organic phase. The aqueous phase was extracted with n-butanol (200 mL) to yield 217.0 mg of the final aqueous fraction (WF) and 756.0 mg of the n-butanol fraction (BF), after removal of the solvents under reduced pressure. The organic phase was concentrated under reduced pressure and was further partitioned between 10% aqueous CH3OH (400 mL) and hexane (2 × 400 mL) to produce, after removing the solvent under reduced pressure, 672.2 mg of the hexane fraction (HF). The H2O content (% v/v) of the methanolic fraction was adjusted to 50% aqueous CH3OH, and the mixture was extracted with CH2Cl2 (100 mL) to afford, after removing the solvent under reduced pressure, 106.3 mg of the CH2Cl2 fraction (DF) and 755.8 mg of the remaining aqueous methanolic fraction (WMF). The dichloromethane fraction (DF) was subjected to solid phase extraction (SPE) with RP-18 (Merck KGaA), using a stepped gradient from H2O to CH3OH and then CH2Cl2 (H2O (100%), H2O/CH3OH (2:1, 1:1, and 1:2), CH3OH (100%), CH3OH/CH2Cl2 (1:1), and CH2Cl2 (100%), yielding seven fractions (R1–R7). The fractions were concentrated under reduced pressure, producing the following weights: R1: 3.8 mg, R2: 1.4 mg, R3: 22.3 mg, R4: 17.7 mg, R5: 39.8 mg, R6: 17.5 mg and R7: 3.8 mg. Fractions R2–R5 were subjected to UHPLC/HRMS analysis and the mobile phase consisted of the following compounds: (A) H2O with 0.1% formic acid (v/v); (B) CH3CN with 0.1% formic acid (v/v) at a flow rate of 400 µL/min. A combination of gradient and isocratic elution was used, starting with 99% A and 1% B, changing to 1% of A and 99% of B in 13 min, followed by 2 min of isocratic at 99% of B, 1 min gradient from 99% to 1% of B and finally, 4 min of isocratic at 99% of A.

3.7. De-Replication

De-replication of the sub-fractions was performed by ultra high-performance liquid chromatography/high-resolution mass spectroscopy (UHPLC/HRMS) on Q Exactive Focus (Thermo Fisher Scientific, Waltham, MA, USA) coupled to UltiMate 3000 UHPLC (Thermo Fisher Scientific, Waltham, MA, USA), using Xcalibur software v.4.0.27.19 (Thermo Fisher Scientific, Waltham, MA, USA). The method consisted of several cycles of full MS scans (R = 70,000) in positive and negative modes in separate runs. External calibration was performed using the LTQ VELOS ESI Positive Ion Calibration Solution (Ref.: 11340360, Thermo Fisher Scientific, Waltham, MA, USA) and Negative Ion Calibration Solution (Ref.: 11360360, Thermo Scientific). The raw MS was analyzed using Compound Discoverer software v2.1 (Thermo Fisher Scientific, Waltham, MA, USA). The separation was performed using a Waters XBridge column C18, 2.1 × 150 mm, 3.5 µm particle size, P/N 186003023 (Optima™ LC/MS Grade, Thermo Fisher Scientific, Waltham, MA, USA). The column temperature was maintained at 30 °C and the mobile phase consisted of the following compounds: (A) H2O with 0.1% formic acid (v/v) and (B) CH3CN with 0.1% formic acid (v/v). The mass spectrometer operated in the positive ESI mode. The exact mass of the components was compared against the Antimarin® database and for the components with no matches in the database, the predicted molecular formula and exact mass were searched in the database platform SciFinder®. If a plausible match was found, considering the exact mass/molecular formula, the molecule was considered as a putative component of the fraction. Finally, 13C NMR spectra were recorded on a Bruker Avance 500 spectrometer at 125 MHz, respectively, using CD3OD for confirming the presence of the main chemical shifts of the compounds found.

4. Conclusions

This work shed light on the great antifungal potential of marine natural products produced by invertebrates of the Yucatan Peninsula. Three of the nine sponge species whose extracts were active against C. albicans and C. glabrata (H. (Rhizoniera) curacaoensis, A. crassa and A. dilatata) have never been associated with antifungal activity, and therefore may represent a new source of antifungal compounds.
The fact that most of these extracts were more effective against C. glabrata is particularly interesting, as this yeast is more tolerant to the current antifungals than C. albicans.
M. arbuscula stood out as the most active species against both C. glabrata and C. albicans. This observation is in line with several reports that highlight the antifungal activity of MNPs isolated from this organism, such as batzelladine L, batzelladine D, norbatzelladine L, and ptiolomycalin A. However, by combining a bioguided fractionation with a de-replication methodology, we found that the activity of M. arbuscula crude extract cannot be ascribed to these compounds. Interestingly, in one of the most active sub-fractions, we found several compounds, of which we identified two—mirabilin B and penaresidin B. Mirabilin B stands out as a promising drug candidate because the pure compound is active against another yeast species—C. neoformans—and its synthesis has already been reported. In the future, it would be interesting to further explore the antifungal and antibiofilm properties of mirabilin B on Candida spp. This would be particularly important given the fungicidal activity of the sub-fraction where mirabilin B was found, which makes the future isolation and identification of the molecules responsible for that activity a possible new strategy to combat life-threatening fungal infections that affect immunocompromised individuals.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules28020606/s1, Figure S1: UHPLC chromatogram of R2 fractions from UHPLC-HRMS experiment. Figure S2: UHPLC chromatogram of R3 fractions from UHPLC-HRMS experiment. Figure S3: UHPLC chromatogram of R5 fractions from UHPLC-HRMS experiment. Figure S4: 13C NMR spectrum of R4 subfraction with the main chemical shifts of 1. Figure S5: HRMS-ESI of the compound 1. Figure S6: 13C NMR spectrum of R4 subfraction with the main chemical shifts of 2. Figure S7: HRMS-ESI of the compound 2. Table S1: Concentration range tested for MIC and MFC determination.

Author Contributions

Conceptualization, D.P.-P., C.J., O.A.L.-R. and C.P.; Chemistry (extraction and fractionation), D.P.-P., M.F.T.; LC-MS and NMR experiments, data analysis, and de-replication, D.P.-P., S.E.C.-P. and O.A.L.-R.; Collection of samples and statistical analysis, D.P.-P., H.V.-H., R.D.-G. and S.G.-H.; Taxonomic identification, H.V.-H.; Biological assays, O.A.L.-R., C.P., D.G. and A.P.; Resources, J.R., C.J., C.P., O.A.L.-R. and D.P.-P.; Writing—original draft, D.P.-P., O.A.L.-R., S.E.C.-P., C.P., C.J. and J.R.; Writing—review and editing, D.P.-P., O.A.L.-R., C.P., C.J., J.R, D.G. and A.P. All authors have read and agreed to the published version of the manuscript.

Funding

The authors acknowledge the Fundação para a Ciência e a Tecnologia, I.P., through (i) MOSTMICRO-ITQB R&D Unit (UIDB/04612/2020), (ii) LS4FUTURE Associated Laboratory (LA/P/0087/2020), (iii) POPH (Programa Operacional Potencial Humano), and FSE (European Social Fund) CEEC 2017 Initiative (to O.A.L.-R.) and (iv) PhD fellowship to A.P. (SFRH/BD/148854/2019). D.P.-P was the recipient of a postdoctoral fellowship from the National Council of Science and Technology (CONACYT) of Mexico.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We thank C. Almeida for their assistance with UHPLC/HRMS. Mass spectrometry data were generated in the Mass Spectrometry Unit (UniMS), ITQB/iBET, Oeiras, Portugal. We gratefully acknowledge the help of our colleagues Daniel Catzim Pech, Gabriel González Mapen, Jorge Peniche Pérez, Melissa Llanes López, Rodrigo Garcia Uribe, Carlos González Salas for collecting the marine samples. We thank Maria Elsa Vázquez Otero (University of Vigo) and Patricia Gomez (ICMyL-UNAM) for helping with taxonomic identification.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Boddy, L. Fungi, Ecosystems, and Global Change, 3rd ed.; Watkinson, S.C., Boddy, L., Money, N.P.B.T.-T.F., Eds.; Academic Press: Cambridge, MA, USA, 2016; pp. 361–400. ISBN 978-0-12-382034-1. [Google Scholar]
  2. Pérez, J.C. Fungi of the human gut microbiota: Roles and significance. Int. J. Med. Microbiol. 2021, 311, 151490. [Google Scholar] [CrossRef] [PubMed]
  3. Brunke, S.; Hube, B. Two unlike cousins: Candida albicans and C. glabrata infection strategies. Cell. Microbiol. 2013, 15, 701–708. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Pappas, P.G.; Lionakis, M.S.; Arendrup, M.C.; Ostrosky-Zeichner, L.; Kullberg, B.J. Invasive candidiasis. Nat. Rev. Dis. Prim. 2018, 4, 18026. [Google Scholar] [CrossRef]
  5. Talapko, J.; Juzbašić, M.; Matijević, T.; Pustijanac, E.; Bekić, S.; Kotris, I.; Škrlec, I. Candida albicans—The virulence factors and clinical manifestations of infection. J. Fungi 2021, 7, 79. [Google Scholar] [CrossRef] [PubMed]
  6. Kullberg, B.J.; Arendrup, M.C. Invasive candidiasis. N, Engl. J. Med. 2015, 373, 1445–1456. [Google Scholar] [CrossRef] [Green Version]
  7. Benedict, K.; Jackson, B.R.; Chiller, T.; Beer, K.D. Estimation of Direct Healthcare Costs of Fungal Diseases in the United States. Clin. Infect. Dis. 2019, 68, 1791–1797. [Google Scholar] [CrossRef] [Green Version]
  8. Pfaller, M.A.; Andes, D.R.; Diekema, D.J.; Horn, D.L.; Reboli, A.C.; Rotstein, C.; Franks, B.; Azie, N.E. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2496 patients: Data from the Prospective Antifungal Therapy (PATH) registry 2004–2008. PLoS ONE 2014, 9, e101510. [Google Scholar] [CrossRef] [Green Version]
  9. Lortholary, O.; Desnos-Ollivier, M.; Sitbon, K.; Fontanet, A.; Bretagne, S.; Dromer, F.; Bouges-Michel, C.; Poilane, I.; Dunan, J.; Galeazzi, G.; et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: A prospective multicenter study involving 2441 patients. Antimicrob. Agents Chemother. 2011, 55, 532–538. [Google Scholar] [CrossRef] [Green Version]
  10. Berman, J.; Krysan, D.J. Drug resistance and tolerance in fungi. Nat. Rev. Microbiol. 2020, 18, 319–331. [Google Scholar] [CrossRef]
  11. Denning, D.W.; Bromley, M.J. How to bolster the antifungal pipeline. Science 2015, 347, 1414–1416. [Google Scholar] [CrossRef]
  12. Zhen, X.; Stålsby Lundborg, C.; Sun, X.; Zhu, N.; Gu, S.; Dong, H. Antibiotic Resistance Threats in the United States, 2019; US Department of Health and Human Services, Centres for Disease Control and Prevention: Atlanta, GA, USA, 2019; Volume 10. [Google Scholar]
  13. Jiménez, C. Marine Natural Products in Medicinal Chemistry. ACS Med. Chem. Lett. 2018, 9, 959–961. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Lu, W.Y.; Li, H.J.; Li, Q.Y.; Wu, Y.C. Application of marine natural products in drug research. Bioorganic Med. Chem. 2021, 35, 116058. [Google Scholar] [CrossRef] [PubMed]
  15. Pech-Puch, D.; Pérez-Povedano, M.; Lenis-Rojas, O.A.; Rodríguez, J.; Jiménez, C. Marine natural products from the Yucatan peninsula. Mar. Drugs 2020, 18, 59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Pech-Puch, D.; Pérez-Povedano, M.; Martinez-Guitian, M.; Lasarte-Monterrubio, C.; Vázquez-Ucha, J.C.; Bou, G.; Rodríguez, J.; Beceiro, A.; Jimenez, C. In vitro and in vivo assessment of the efficacy of bromoageliferin, an alkaloid isolated from the sponge Agelas dilatata, against Pseudomonas aeruginosa. Mar. Drugs 2020, 18, 326. [Google Scholar] [CrossRef]
  17. Pech-Puch, D.; Pérez-Povedano, M.; Gómez, P.; Martínez-Guitián, M.; Lasarte-Monterrubio, C.; Vázquez-Ucha, J.C.; Novoa-Olmedo, M.L.; Guillén-Hernández, S.; Villegas-Hernández, H.; Bou, G.; et al. Marine organisms from the Yucatan Peninsula (Mexico) as a potential natural source of antibacterial compounds. Mar. Drugs 2020, 18, 369. [Google Scholar] [CrossRef]
  18. Pech-Puch, D.; Berastegui-Cabrera, J.; Pérez-Povedano, M.; Villegas-Hernández, H.; Guillén-Hernández, S.; Cautain, B.; Reyes, F.; Pachón, J.; Gómez, P.; Rodríguez, J.; et al. Antiviral and Antiproliferative Potential of Marine Organisms from the Yucatan Peninsula, Mexico. Front. Mar. Sci. 2020, 7, 607. [Google Scholar] [CrossRef]
  19. Morales, J.L.; Cantillo-Ciau, Z.O.; Sánchez-Molina, I.; Mena-Rejón, G.J. Screening of antibacterial and antifungal activities of six marine macroalgae from coasts of Yucatán peninsula. Pharm. Biol. 2006, 44, 632–635. [Google Scholar] [CrossRef]
  20. Hernández, G. Mauricio Actividad Antifúngica de Extractos de Macroalgas Marinas de la Costa de Yucatán. Master’s Thesis, Centro de Investigación Científica de Yucatán, Yucatán, Mexico, 2018. [Google Scholar]
  21. Stout, E.P.; Yu, L.C.; Molinski, T.F. Antifungal diterpene alkaloids from the Caribbean sponge Agelas citrina: Unified configurational assignments of agelasidines and agelasines. Eur. J. Org. Chem. 2012, 2012, 5131–5135. [Google Scholar] [CrossRef] [Green Version]
  22. Aldholmi, M.; Marchand, P.; Ourliac-Garnier, I.; Le Pape, P.; Ganesan, A. A decade of antifungal leads from natural products: 2010–2019. Pharmaceuticals 2019, 12, 2010–2019. [Google Scholar] [CrossRef] [Green Version]
  23. Xu, N.J.; Sun, X.; Yan, X.J. A new cyclostellettamine from sponge Amphimedon compressa. Chin. Chem. Lett. 2007, 18, 947–950. [Google Scholar] [CrossRef]
  24. Shady, N.H.; Fouad, M.A.; Kamel, M.S.; Schirmeister, T.; Abdelmohsen, U.R. Natural product repertoire of the genus Amphimedon. Mar. Drugs 2019, 17, 19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Walker, R.P.; John Faulkner, D.; Van Engen, D.; Clardy, J. Sceptrin, an Antimicrobial Agent from the Sponge Agelas sceptrum. J. Am. Chem. Soc. 1981, 103, 6772–6773. [Google Scholar] [CrossRef]
  26. Galeano, E.; Martínez, A. Antimicrobial activity of marine sponges from Urabá Gulf, Colombian Caribbean region. J. Mycol. Med. 2007, 17, 21–24. [Google Scholar] [CrossRef]
  27. Santos, M.F.C. Alcaloides Guanidínicos da Esponja Marinha Monanchora arbuscula: Isolamento, Identificação e Atividades Biológicas. Ph.D. Thesis, Universidade de São Paulo, São Paulo, Brazil, 2014. [Google Scholar]
  28. Domingos, L.T.S.; Santos, M.F.C.; de Moraes, D.C.; de Sá, L.F.R.; da Silva, V.A.D.; Meuren, L.M.; Berlinck, R.G.S.; Ferreira-Pereira, A. Batzelladine D and norbatzelladine L purified from marine sponge Monanchora arbuscula induce the reversal of fluconazole. Bioorg. Chem. 2020, 105, 104402. [Google Scholar] [CrossRef] [PubMed]
  29. Dalisay, D.S.; Saludes, J.P.; Molinski, T.F. Ptilomycalin A inhibits laccase and melanization in Cryptococcus neoformans. Bioorganic Med. Chem. 2011, 19, 6654–6657. [Google Scholar] [CrossRef] [Green Version]
  30. Turner, S.A.; Butler, G. The Candida pathogenic species complex. Cold Spring Harb. Perspect. Med. 2014, 4, a019778. [Google Scholar] [CrossRef] [Green Version]
  31. Kobayashi, J.; Cheng, J.F.; Ishibashi, M.; Wälchli, M.R.; Yamamura, S.; Onizumi, Y. Penaresidin A and B, two novel azetidine alkaloids with potent actomyosin ATPase-activating activity from the Okinawan marine sponge Penares sp. J. Chem. Soc. Perkin Trans. 1 1991, 1135–1137. [Google Scholar] [CrossRef]
  32. Fujiwara, T.; Hashimoto, K.; Umeda, M.; Murayama, S.; Ohno, Y.; Liu, B.; Nambu, H.; Yakura, T. Divergent total synthesis of penaresidin B and its straight side chain analogue. Tetrahedron 2018, 74, 4578–4591. [Google Scholar] [CrossRef]
  33. Patil, A.D.; Freyer, A.J.; Offen, P.; Bean, M.F.; Johnson, R.K. Three new tricyclic guanidine alkaloids from the sponge Batzella sp. J. Nat. Prod. 1997, 60, 704–707. [Google Scholar] [CrossRef]
  34. Hua, H.M.; Peng, J.; Fronczek, F.R.; Kelly, M.; Hamann, M.T. Crystallographic and NMR studies of antiinfective tricyclic guanidine alkaloids from the sponge Monanchora unguifera. Bioorganic Med. Chem. 2004, 12, 6461–6464. [Google Scholar] [CrossRef]
  35. Ohshita, K.; Ishiyama, H.; Takahashi, Y.; Ito, J.; Mikami, Y.; Kobayashi, J. Synthesis of penaresidin derivatives and its biological activity. Bioorganic Med. Chem. 2007, 15, 4910–4916. [Google Scholar] [CrossRef] [PubMed]
  36. Zar, J.H. Biostatistical Analysis; Prentice-Hall, Inc.: Hoboken, NJ, USA, 1996; p. 662. [Google Scholar]
  37. Kossuga, M.H.; MacMillan, J.B.; Rogers, E.W.; Molinski, T.F.; Nascimento, G.G.F.; Rocha, R.M.; Berlinck, R.G.S. (2S,3R)-2-aminododecan-3-ol, a new antifungal agent from the ascidian Clavelina oblonga. J. Nat. Prod. 2004, 67, 1879–1881. [Google Scholar] [CrossRef] [PubMed]
  38. Raub, M.F.; Cardellina, J.H.; Spande, T.F. The piclavines, antimicrobial indolizidines from the tunicate Clavelina picta. Tetrahedron Lett. 1992, 33, 2257–2260. [Google Scholar] [CrossRef]
  39. Suzuki, K.; Nomura, I.; Ninomiya, M.; Tanaka, K.; Koketsu, M. Synthesis and antimicrobial activity of β-carboline derivatives with N 2 -alkyl modifications. Bioorganic Med. Chem. Lett. 2018, 28, 2976–2978. [Google Scholar] [CrossRef] [PubMed]
  40. Schumacher, R.W.; Davidson, B.S. Didemnolines A-D, new N9-substituted β-carbolines from the marine ascidian Didemnum sp. Tetrahedron 1995, 51, 10125–10130. [Google Scholar] [CrossRef]
  41. Shaala, L.A.; Youssef, D.T.A.; Ibrahim, S.R.M.; Mohamed, G.A.; Badr, J.M.; Risinger, A.L.; Mooberry, S.L. Didemnaketals F and G, new bioactive spiroketals from a Red Sea ascidian Didemnum species. Mar. Drugs 2014, 12, 5021–5034. [Google Scholar] [CrossRef] [Green Version]
  42. Cafieri, F.; Fattorusso, E.; Mangoni, A.; Taglialatela-Scafati, O. Clathramides, unique bromopyrrole alkaloids from the Caribbean sponge Agelas clathrodes. Tetrahedron 1996, 52, 13713–13720. [Google Scholar] [CrossRef]
  43. Ciminiello, P.; Fattorusso, E.; Magno, S.; Mangoni, A. Clathridine and its zinc complex, novel metabolites from the marine sponge Clathrina clathrus. Tetrahedron 1989, 45, 3873–3878. [Google Scholar] [CrossRef]
  44. Rodriguez, A.D.; Yoshida, W.Y.; Scheuer, P.J. Popolohuanone A and B. two new sesquiterpenoid aminoquinones from a pacific sponge Dysidea sp. Tetrahedron 1990, 46, 8025–8030. [Google Scholar] [CrossRef]
  45. Hirsch, S.; Rudi, A.; Kashman, Y.; Loya, Y. New avarone and avarol derivatives from the marine sponge Dysidea cinerea. J. Nat. Prod. 1991, 54, 92–97. [Google Scholar] [CrossRef]
  46. Jacob, M.R.; Hossain, C.F.; Mohammed, K.A.; Smillie, T.J.; Clark, A.M.; Walker, L.A.; Nagle, D.G. Reversal of Fluconazole Resistance in Multidrug Efflux-Resistant Fungi by the Dysidea arenaria Sponge Sterol 9α,11α-Epoxycholest-7-ene-3β,5α,6α,19-tetrol 6-Acetate. J. Nat. Prod. 2003, 66, 1618–1622. [Google Scholar] [CrossRef]
  47. Sionov, E.; Roth, D.; Sandovsky-Losica, H.; Kashman, Y.; Rudi, A.; Chill, L.; Berdicevsky, I.; Segal, E. Antifungal effect and possible mode of activity of a compound from the marine sponge Dysidea herbacea. J. Infect. 2005, 50, 453–460. [Google Scholar] [CrossRef] [PubMed]
  48. Ciavatta, M.L.; Lopez Gresa, M.P.; Gavagnin, M.; Romero, V.; Melck, D.; Manzo, E.; Guo, Y.W.; van Soest, R.; Cimino, G. Studies on puupehenone-metabolites of a Dysidea sp.: Structure and biological activity. Tetrahedron 2007, 63, 1380–1384. [Google Scholar] [CrossRef]
  49. Lee, D.; Shin, J.; Yoon, K.M.; Kim, T.I.; Lee, S.H.; Lee, H.S.; Oh, K.B. Inhibition of Candida albicans isocitrate lyase activity by sesterterpene sulfates from the tropical sponge Dysidea sp. Bioorganic Med. Chem. Lett. 2008, 18, 5377–5380. [Google Scholar] [CrossRef]
  50. Pandeya, S.N.; Tripathi, K.; Kulshreshtha, S. Synthesis and antifungal activity of isatin-3-semicarbazone. Asian J. Chem. 2009, 21, 3367–3370. [Google Scholar]
  51. Nazemi, M.; Motallebi, A.A.; Savari, A.; Ghoroghi, A.; Safdari, R.; Ghasemi, S.; Sadrian, M.B. Biological activity (Antibacterial, Antifungal, Antiviral and Cytotoxic) of extract from Dysidea spp. Iran. Fish. Res. Organ. 2014. [Google Scholar]
  52. Skepper, C.K.; Dalisay, D.S.; Molinski, T.F. Synthesis and Antifungal Activity of (−)-(Z)-Dysidazirine. Org. Lett. 2008, 10, 5269–5271. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Pejin, B.; Ciric, A.; Markovic, D.; Tommonaro, G.; Sokovic, M. In vitro avarol does affect the growth of Candida sp. Nat. Prod. Res. 2016, 30, 1956–1960. [Google Scholar] [CrossRef] [PubMed]
  54. Medeiros, M.L. Análise Química Preliminar de Extratos de Caulerpa Mexicana, Bryopsis Pennata, Vryothamion Triquerum, Hypnea Musciformes e Ircina Felix e Avaliação das Atividades Antifúngica e Antibacteriana; Universidade Federal da Paraíba: João Pessoa, Brazil, 2014. [Google Scholar]
  55. Gharpure, S.; Akash, A.; Ankamwar, B. A Review on Antimicrobial Properties of. J. Nanosci. Nanotechnol. 2020, 20, 3303–3339. [Google Scholar] [CrossRef]
  56. Ayyad, S.E.N.; Katoua, D.F.; Alarif, W.M.; Sobahi, T.R.; Aly, M.M.; Shaala, L.A.; Ghandourah, M.A. Two new polyacetylene derivatives from the Red Sea sponge Xestospongia sp. Z. Für Nat. C 2015, 70, 297–303. [Google Scholar] [CrossRef]
  57. Singh, A.; Tilvi, S.; Singh, K.S. Quinolizidine Alkaloids from Marine Organisms: A Perspective on Chemical, Bioactivity and Synthesis. Front. Nat. Prod. Chem. 2021, 8, 45–98. [Google Scholar]
  58. Chen, Y.; Killday, K.B.; McCarthy, P.J.; Schimoler, R.; Chilson, K.; Selitrennikoff, C.; Pomponi, S.A.; Wright, A.E. Three new peroxides from the sponge Plakinastrella species. J. Nat. Prod. 2001, 64, 262–264. [Google Scholar] [CrossRef] [PubMed]
  59. Chen, Y.; McCarthy, P.J.; Harmody, D.K.; Schimoler-O’Rourke, R.; Chilson, K.; Selitrennikoff, C.; Pomponi, S.A.; Wright, A.E. New bioactive peroxides from marine sponges of the family Plakiniidae. J. Nat. Prod. 2002, 65, 1509–1512. [Google Scholar] [CrossRef] [PubMed]
  60. Xu, T.; Feng, Q.; Jacob, M.R.; Avula, B.; Mask, M.M.; Baerson, S.R.; Tripathi, S.K.; Mohammed, R.; Hamann, M.T.; Khan, I.A.; et al. The marine sponge-derived polyketide endoperoxide plakortide F acid mediates its antifungal activity by interfering with calcium homeostasis. Antimicrob. Agents Chemother. 2011, 55, 1611–1621. [Google Scholar] [CrossRef] [Green Version]
  61. El-Hossary, E.M.; Cheng, C.; Hamed, M.M.; El-Sayed Hamed, A.N.; Ohlsen, K.; Hentschel, U.; Abdelmohsen, U.R. Antifungal potential of marine natural products. Eur. J. Med. Chem. 2017, 126, 631. [Google Scholar] [CrossRef]
  62. Hua, H.M.; Peng, J.; Dunbar, D.C.; Schinazi, R.F.; de Castro Andrews, A.G.; Cuevas, C.; Garcia-Fernandez, L.F.; Kelly, M.; Hamann, M.T. Batzelladine alkaloids from the caribbean sponge Monanchora unguifera and the significant activities against HIV-1 and AIDS opportunistic infectious pathogens. Tetrahedron 2007, 63, 11179–11188. [Google Scholar] [CrossRef]
  63. Oliveira, J.R. Contribuição ao Conhecimento Químico de Esponjas do Litoral Cearense: Monanchora arbuscula. Master’s Thesis, Universidade Federal do Ceará, Fortaleza, Brazil, 2008. [Google Scholar]
  64. Arevabini, C.; Crivelenti, Y.D.; De Abreu, M.H.; Bitencourt, T.A.; Santos, M.F.C.; Berlinck, R.G.S.; Hajdu, E.; Beleboni, R.O.; Fachin, A.L.; Marins, M. Antifungal activity of metabolites from the marine sponges Amphimedon sp. and Monanchora arbuscula against Aspergillus flavus strains isolated from peanuts (Arachis hypogaea). Nat. Prod. Commun. 2014, 9, 33–36. [Google Scholar] [CrossRef] [Green Version]
  65. Dyshlovoy, S.A.; Fedorov, S.N.; Shubina, L.K.; Kuzmich, A.S.; Bokemeyer, C.; Keller-Von Amsberg, G.; Honecker, F. Aaptamines from the marine sponge Aaptos sp. display anticancer activities in human cancer cell lines and modulate AP-1-, NF- B-, and p53-dependent transcriptional activity in mouse JB6 Cl41 cells. Biomed Res. Int. 2014, 2014, 469309. [Google Scholar] [CrossRef] [Green Version]
  66. Yu, H.B.; Yang, F.; Sun, F.; Li, J.; Jiao, W.H.; Gan, J.H.; Hu, W.Z.; Lin, H.W. Aaptamine derivatives with antifungal and Anti-HIV-1 activities from the South China Sea sponge Aaptos aaptos. Mar. Drugs 2014, 12, 6003–6013. [Google Scholar] [CrossRef]
  67. He, Q.; Miao, S.; Ni, N.; Man, Y.; Gong, K. A Review of the Secondary Metabolites From the Marine Sponges of the Genus Aaptos. Nat. Prod. Commun. 2020, 15, 1934578X20951439. [Google Scholar] [CrossRef]
  68. Kazanjian, A.; Fariñas, M. Actividades biológicas del extracto acuoso de la esponja Aplysina lacunosa (Porifera: Aplysinidae). Rev. Biol. Trop. 2006, 54, 189–200. [Google Scholar]
  69. Palpandi, C.; Krishnan, S.; Ananthan, G. Antifungal activity of some species of marine sponges (class: Demospongiae ) of the palk bay, southeast coast of India. Int. J. Med. Med. Sci. 2013, 5, 409–413. [Google Scholar] [CrossRef]
  70. El-Bondkly, A.A.M.; El-Gendy, M.M.A.A.; El-Bondkly, A.M.A. Construction of Efficient Recombinant Strain Through Genome Shuffling in Marine Endophytic Fusarium sp. ALAA-20 for Improvement Lovastatin Production Using Agro-Industrial Wastes. Arab. J. Sci. Eng. 2021, 46, 175–190. [Google Scholar] [CrossRef]
  71. Rogers, E.W.; Molinski, T.F. Highly polar spiroisoxazolines from the sponge Aplysina fulva. J. Nat. Prod. 2007, 70, 1191–1194. [Google Scholar] [CrossRef] [PubMed]
  72. Gomes Filho, S.M. Purificação, Caracterização e Atividades Biológicas de uma Lectina da Esponja Marinha Aplysina fulva (AFL); Universidade Federal de Paríba: João Pessoa, Brazil, 2014. [Google Scholar]
  73. Cedeño-Ramos, R.; D’Armas, H.; Amaro, M.; Martínez, R. Metabolitos secundarios, letalidad y actividad antimicrobiana de seis esponjas marinas de la Bahía de Mochima, Venezuela. Res. J. Costa Rican Distance Educ. Univ. 2015, 7, 225–232. [Google Scholar]
  74. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 4th ed.; CLSI standard M27; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2017. [Google Scholar]
Molecules 28 00606 g001 550
Figure 1. Chemical structure of representatives of the three classes of antifungal drugs used in the treatment of invasive fungal infections: amphotericin B (polyene), caspofungin (echinocandin), and fluconazole (azole).
Figure 1. Chemical structure of representatives of the three classes of antifungal drugs used in the treatment of invasive fungal infections: amphotericin B (polyene), caspofungin (echinocandin), and fluconazole (azole).
Molecules 28 00606 g001
Molecules 28 00606 g002 550
Figure 2. Susceptibility of C. glabrata to marine extracts from the Yucatan Peninsula. Growth was monitored after 48 h of incubation at 37 °C. Growth ratios were determined in comparison to control (untreated) cells. Fluconazole (a triazole antifungal) was used as a reference antifungal (16 µg/mL). Growth ratios below 0.5 indicate active extracts (blue bars).
Figure 2. Susceptibility of C. glabrata to marine extracts from the Yucatan Peninsula. Growth was monitored after 48 h of incubation at 37 °C. Growth ratios were determined in comparison to control (untreated) cells. Fluconazole (a triazole antifungal) was used as a reference antifungal (16 µg/mL). Growth ratios below 0.5 indicate active extracts (blue bars).
Molecules 28 00606 g002
Molecules 28 00606 g003 550
Figure 3. Susceptibility of C. albicans to marine extracts from the Yucatan Peninsula. Growth was monitored after 48 h of incubation at 30 °C. Growth ratios were determined in comparison to control (untreated) cells. Fluconazole (a triazole antifungal) was used as a reference antifungal (0.5 µg/mL). Growth ratios below 0.5 indicate active extracts (blue bars).
Figure 3. Susceptibility of C. albicans to marine extracts from the Yucatan Peninsula. Growth was monitored after 48 h of incubation at 30 °C. Growth ratios were determined in comparison to control (untreated) cells. Fluconazole (a triazole antifungal) was used as a reference antifungal (0.5 µg/mL). Growth ratios below 0.5 indicate active extracts (blue bars).
Molecules 28 00606 g003
Molecules 28 00606 g004 550
Figure 4. Susceptibility of C. glabrata to M. arbuscula fractions. Growth was monitored after 48 h of incubation at 37 °C. Growth ratios were determined in comparison to control (untreated) cells. Growth ratios below 0.5 indicate active fractions.
Figure 4. Susceptibility of C. glabrata to M. arbuscula fractions. Growth was monitored after 48 h of incubation at 37 °C. Growth ratios were determined in comparison to control (untreated) cells. Growth ratios below 0.5 indicate active fractions.
Molecules 28 00606 g004
Molecules 28 00606 g005 550
Figure 5. Susceptibility of C. albicans to M. arbuscula fractions. Growth was monitored after 48 h of incubation at 30 °C. Growth ratios were determined in comparison to control (untreated) cells. Growth ratios below 0.5 indicate active fractions.
Figure 5. Susceptibility of C. albicans to M. arbuscula fractions. Growth was monitored after 48 h of incubation at 30 °C. Growth ratios were determined in comparison to control (untreated) cells. Growth ratios below 0.5 indicate active fractions.
Molecules 28 00606 g005
Molecules 28 00606 g006 550
Figure 6. Growth of Candida spp. with different sub-fractions of E35-DF. Yeast cells were incubated with the sub-fractions for 24 h and 48 h and a volume of 5 μL was spotted onto YPD agar plates. Images were digitalized after 24 h of incubation at 37 °C for C. glabrata (A) or 30 °C for C. albicans (B). The concentrations tested are listed in Table 4. Inoculum: growth prior to sub-fraction addition; untreated control cells.
Figure 6. Growth of Candida spp. with different sub-fractions of E35-DF. Yeast cells were incubated with the sub-fractions for 24 h and 48 h and a volume of 5 μL was spotted onto YPD agar plates. Images were digitalized after 24 h of incubation at 37 °C for C. glabrata (A) or 30 °C for C. albicans (B). The concentrations tested are listed in Table 4. Inoculum: growth prior to sub-fraction addition; untreated control cells.
Molecules 28 00606 g006
Molecules 28 00606 g007 550
Figure 7. UHPLC-HRMS analysis of sub-fraction R4. (A) UHPLC chromatogram. Peaks analyzed by HRMS are marked with a red circle. (B) HRMS of the chromatographic peak from the sub-fraction R4 eluted with a retention time of 9.12, showing an [M + H]+ ion adduct that matches the molecular formula of C15H23N3 for mirabilin B. (C) HRMS of the chromatographic peak from the sub-fraction R4 eluted with a retention time of 11.0 with an [M + H]+ ion adduct that matches the molecular formula of C19H39NO3 for penaresidin B.
Figure 7. UHPLC-HRMS analysis of sub-fraction R4. (A) UHPLC chromatogram. Peaks analyzed by HRMS are marked with a red circle. (B) HRMS of the chromatographic peak from the sub-fraction R4 eluted with a retention time of 9.12, showing an [M + H]+ ion adduct that matches the molecular formula of C15H23N3 for mirabilin B. (C) HRMS of the chromatographic peak from the sub-fraction R4 eluted with a retention time of 11.0 with an [M + H]+ ion adduct that matches the molecular formula of C19H39NO3 for penaresidin B.
Molecules 28 00606 g007
Molecules 28 00606 g008 550
Figure 8. Chemical structure of compounds mirabilin B (1) and penaresidin B (2).
Figure 8. Chemical structure of compounds mirabilin B (1) and penaresidin B (2).
Molecules 28 00606 g008
Molecules 28 00606 g009 550
Figure 9. Collection sites of marine organisms in the Yucatan Peninsula, Mexico.
Figure 9. Collection sites of marine organisms in the Yucatan Peninsula, Mexico.
Molecules 28 00606 g009
Molecules 28 00606 g010 550
Figure 10. Selected structures of compounds with reported antifungal activity isolated from marine organisms.
Figure 10. Selected structures of compounds with reported antifungal activity isolated from marine organisms.
Molecules 28 00606 g010
Table
Table 1. Marine crude extracts tested for antifungal activity.
Table 1. Marine crude extracts tested for antifungal activity.
CodeSpeciesYield (g)Extract Concentration (mg/mL)Concentration Used in the Screening (µg/mL)
E38Aaptos sp.4.91.6641.5
CZE56Agelas citrina1.95125
E27-2Agelas clathrodes11.21.6641.5
MA18-10Agelas clathrodes7.22.562.5
E25-1Agelas dilatata21.31.6641.5
E26-2Agelas sceptrum4.62.562.5
E50Aiolochroia crassa5.25125
MA18-4Aiolochroia crassa8.71.4335.75
E29Amphimedon compressa12.91.6641.5
E36Aplysina cauliformis6.32.562.5
E46Aplysina fistularis2.72.562.5
E42Aplysina fulva1.85125
EY18-5Aplysina fulva2.9125
E47Aplysina muricyanna4.42.562.5
BA-3Briareum asbestinum3.95125
E28Callyspongia longissima1.81.6641.5
E31Callyspongia plicifera1.2125
E16Callyspongia vaginalis0.91.6641.5
MA18-6Chondrilla caribensis f. hermatypica2.12.562.5
RIO18-1Chondrilla sp.4.62.562.5
MA18-2Cinachyrella kuekenthali2.10.512.5
EY18-11Clathria gomezae1.85125
E7-E34Clathria virgultosa5.5125
EY18-10Clathrina sp.1.4250
T18-M1Clavelina sp.5.0125
EY18-1Cliona delitrix5.2250
EY18-3Cliona varians1.81.6641.5
E8-2Didemnum perlucidum1.82.562.5
E01Didemnum sp.3.72.562.5
T18-M4Didemnum sp.3.52.562.5
EY18-12Dysidea sp.3.35125
T18-M2Ecteinascidia sp.9.02.562.5
MA18-9Ectyoplasia ferox5.91.6641.5
MA18-13Ectyoplasia sp.2.25125
RIO18-T1Eudistoma amanitum3.62.562.5
TY18-2Eudistoma sp.2.95125
E18-M1Halichondria melanadocia14.1125
EY18-4Haliclona (Rhizoniera) curacaoensis7.95125
E9-2Ircinia felix43.51.6641.5
MA18-11Ircinia felix1.72.562.5
E24-2Ircinia strobilina14.15125
E52Ircinia strobilina4.92.562.5
E2-2Leucetta floridana1.31.2531.25
E4Melophlus hajdui4.42.562.5
T18-M6Molgula sp.3.95125
E35Monanchora arbuscula29.82.562.5
MA18-1Mycale laevis14.1125
MA18-5Mycale laevis4.95125
CZE18Myrmekioderma gyroderma7.52.562.5
E15Niphates digitalis2.5125
E49Niphates erecta1.6125
MA18-12Niphates erecta5.55125
MA18-7Niphates erecta2.82.562.5
TY18-1Phallusia nigra5.52.562.5
E3Plakinastrella onkodes4.95125
E41Polycarpa sp.2.4250
T18-M5Polyclinum sp.1.85125
EY18-8Polysyncraton sp.3.62.562.5
DNYScopalina ruetzleri29.81.6641.5
E53Scopalina ruetzleri1.85125
EY18-7Scopalina ruetzleri5.51.2531.25
E11-2Spongia tubulifera29.82.562.5
E20Tethya sp.29.85125
E7-2Trididemnum solidum3.42.562.5
EPXestospongia muta14.1125
Table
Table 2. MIC values (µg/mL) of the organic extracts of marine organisms from the Yucatán Peninsula for C. albicans and C. glabrata.
Table 2. MIC values (µg/mL) of the organic extracts of marine organisms from the Yucatán Peninsula for C. albicans and C. glabrata.
MIC (µg/mL)
Code/
Reference		SpeciesC. glabrataC. albicans
24 h48 h24 h48 h
MA18-4A. crassa4.4717.8835.7835.78
E29A. compressa2.592.595.195.19
E35M. arbuscula3.913.913.913.91
CZE56A. citrina7.817.813.913.91
Fluconazole-8160.50.5
Table
Table 3. Fractions obtained from the crude extract of M. arbuscula (E35).
Table 3. Fractions obtained from the crude extract of M. arbuscula (E35).
FractionConcentration (mg/mL)Concentration Used in the Bioassay (µg/mL)
E35-WF4.8120
E35-DF2.460
E35-HF2.562.5
E35-BF4.7117.5
E35-WMF5.2130
Table
Table 4. Sub-fractions obtained from the fraction E35-DF.
Table 4. Sub-fractions obtained from the fraction E35-DF.
Sub-FractionConcentration (mg/mL)Concentration Used in the
Bioassay (µg/mL)
R15.4135
R25.2130
R33.690
R42.460
R54.6115
R65.4135
R75.4135
Table
Table 5. MIC values (µg/mL) of fraction E35-DF and of the resulting sub-fractions R2 to R5 for C. albicans and C. glabrata.
Table 5. MIC values (µg/mL) of fraction E35-DF and of the resulting sub-fractions R2 to R5 for C. albicans and C. glabrata.
MIC (µg/mL)
(Sub-)Fraction/
Reference		C. glabrataC. albicans
24 h48 h24 h48 h
E35-DF3.753.757.5015
R22.034.062.034.06
R32.815.632.815.63
R43.753.757.5015
R51.083.591.803.59
Fluconazole8160.50.5
Table
Table 6. MIC values (µg/mL) of the sub-fractions R2 to R5 for C. krusei, C. tropicalis and C. parapsilosis.
Table 6. MIC values (µg/mL) of the sub-fractions R2 to R5 for C. krusei, C. tropicalis and C. parapsilosis.
MIC (µg/mL)
Sub-FractionC. kruseiC. tropicalisC. parapsilosis
24 h48 h24 h48 h24 h48 h
R214.6929.3814.6914.6914.6929.38
R331.2512515.6331.2515.6315.63
R411.2511.255.6311.255.635.63
R57.1928.753.597.193.597.19
Table
Table 7. MFC values (µg/mL) of the sub-fractions R2 to R5.
Table 7. MFC values (µg/mL) of the sub-fractions R2 to R5.
MFC (µg/mL)
24 h48 h
R2R3R4R5R2R3R4R5
C. albicans14.6931.2511.2514.38*31.255.637.19
C. glabrata58.75125.0011.253.5958.75125.0022.503.59
C. krusei117.5*22.557.5058.75*22.557.50
C. tropicalis14.6915.6311.257.1914.6915.6311.257.19
C. parapsilosis29.387.8111.257.1929.3831.2545.0057.50
* No fungicidal activity detected within the concentration range tested.
Table
Table 8. [M + H]+ ion adducts detected in UHPLC-HRMS analyses of R2, R3, R4 and R5 sub-fractions.
Table 8. [M + H]+ ion adducts detected in UHPLC-HRMS analyses of R2, R3, R4 and R5 sub-fractions.
Sub-FractionsUHPLC
(Retention Time in min)		[M + H]+ ion Adducts(m/z)Possible Compound *
R29.56256.8662-
10.49259.2150-
15.49282.2792-
R312.00330.3001Penaresidin B (m/z 330.3002) isolated from Penares sp. [31,32]
12.21404.3271-
R49.12246.1965Mirabilin B (m/z 246.1964) isolated from Arennochalina mirabilis [33]
9.98248.2177-
10.25346.2488-
10.75348.2644-
11.00376.2960-
11.25318.3001-
11.00330.3001Penaresidin B (m/z 330.3002) isolated from Penares sp. [31,32]
R510.87325.2749-
11.22318.3006-
11.71332.3156-
11.90330.3001Penaresidin B (m/z 330.3002) isolated from Penares sp. [31,32]
12.14404.3265-
12.42344.3158-
15.49282.2793-
* The positive criterion corresponds to an m/z-accuracy of 3 decimal places.
Table
Table 9. Experimentala and reportedb 13C NMR (125 MHz) data for mirabilin B (1) and penaresidin B (2).
Table 9. Experimentala and reportedb 13C NMR (125 MHz) data for mirabilin B (1) and penaresidin B (2).
Post.12
aδC, Type *bδC, Type **aδC, Type *bδC, Type **
1 61.3, CH262.3, CH2
2176.3, C176.2, C66.3, CH66.6, CH
3126.9, C126.8, C66.9, CH67.4, CH
4167.3, C167.3, C65.4, CH64.8, CH
5 27.2, CH226.9, CH2
6164.6, C164.6, C27.2, CH226.9, CH2
7 27.2, CH226.9, CH2
839.2, CH39.0, CH27.2, CH226.9, CH2
940.4, CH240.8, CH227.2, CH226.9, CH2
1035.1, CH35.2, CH27.2, CH226.9, CH2
1148.8, CH48.2, CH27.2, CH226.9, CH2
1234.4, CH234.3, CH227.2, CH226.9, CH2
1334.2, CH234.1, CH227.2, CH226.9, CH2
14 72.6, CH72.7, CH
1521.6, CH321.3, CH334.9, CH234.9, CH2
1631.6, CH331.1, CH324.8, CH24.6, CH
1728.6, CH228.6, CH225.6, CH225.5, CH2
1824.2, CH224.4, CH211.5, CH311.6, CH3
1914.4, CH314.4, CH322.3, CH322.3, CH3
* NMR experiment run in CDCl3 solvent; ** NMR experiment run in CD3OD solvent.
Table
Table 10. Taxonomic information and previously reported antifungal activity of the marine species studied in this work.
Table 10. Taxonomic information and previously reported antifungal activity of the marine species studied in this work.
OrderFamilySpecies
(Code Used in This Study)		Antifungal Activity Previously ReportedReference
AplousobranchiaClavelinidaeClavelina sp.
(T18-M1)		(2S,3R)-2-aminododecan-3-ol isolated from Clavelina oblonga active against C. albicans and C. glabrata.
Indolizines isolated from C. picta active against C. albicans. 		[37,38]
DidemnidaeDidemnum perlucidum
(E8-2)		No
Didemnum sp.
(T18-M4)
(E01)		Didemnoline B and C active on S. cerevisiae.
Lepadin D and E active against Ustilago violacea (now Microbotryum violaceum) and Eurotium repens, respectively.
Lepadin F active against E. repens.
Didemnaketal F and G active against C. albicans.
β-carboline active against C. albicans, C. intermedia and C. krusei.
β-carboline dimer active against C. intermedia.
β-carboline N-Me salts showed activity against C. intermedia and C. krusei.		[38,39,40,41]
Trididemnum solidum
(E7-2)		No
PolycitoridaePolysyncraton sp.
(EY18-8)		No
Eudistoma amanitum
(RIO18-T1) 		No
Eudistoma sp.
(TY18-2)		Eudistomin W and X active against C. albicans. [27]
PolyclinidaePolyclinum sp.
(T18-M5)		No
PhlebobranchiaAscidiidaePhallusia nigra
(TY18-1)		No
PerophoridaeEcteinascidia sp.
(T18-M2)		No
StolidobranchiaMolgulidaeMolgula sp.
(T18-M6)		No
StyelidaePolycarpa sp.
(E41)		No
AlcyonaceaBriareridaeBriareum asbestinum
(BA-3)		No
AgelasidaAgelisidaeAgelas citrina
(CZE56)		(–)-Agelasidine C, agelasidine E and F active against C. albicans.[21,22]
Agelas clathrodes
(E27-2)
(MA18-10)		Clathramides A and B showed activity against Aspergillus niger.[42]
Agelas dilatata
(E25-1)		No
Agelas sceptrum
(E26-2)		Sceptrin is active against C. albicans, Alternaria sp. and Cladosporium cucumerinum.[25]
AxinelidaHeteroxyidaeMyrmekioderma gyroderma
(CZE18)		No
RaspailiidaeEctyoplasia ferox
(MA18-9)		No
Ectyoplasia sp.
(MA18-13)		No
ChondrilidaChondrilidaeChondrilla caribensis f. hermatypica
(MA18-6)		No
Chondrilla sp.
(RIO18-1)		No
ClathrinidaClathrinidaeClathrina sp.
(EY18-10)		Clathridine is active against C. albicans and S. cerevisiae.[43]
LeucittidaeLeucetta floridana
(E2-2)		Extract showed activity against C. albicans.[26]
ClionaidaClionaidaeCliona delitrix
(EY18-1)		No
Cliona varians
(EY18-3)		No
DictyoceratidaDysideidaeDysidea sp.
(EY18-12)		3′-hydroxyavarone, 3′,6′di-hydroxyavarone and 6′-acetoxyavarol are active against C. albicans.
9α,11α-epoxycholest-7-ene-3β,5α,6α,19-tetrol 6-acetate (ECTA) is active against C. albicans.
3,5-dibromo-2-(3,5-dibromo-2-methoxyphenoxy) phenol is active against C. albicans, C. glabrata, C. tropicalis, A. fumigatus, A. flavus and A. niger.
Puupehenone is active against C. albicans.
Synthetic (Z)-dysidazirine [(-)-1] is active against C. albicans, C. glabrata and C. krusei.
Sesterterpenes sulphates showed inhibitory activity against C. albicans.
Avarol is active against eight Candida spp. 		[44,45,46,47,48,49,50,51,52,53]
IrciniidaeIrcinia felix
(E9-2)
(MA18-11)		Extract showed activity against C. tropicalis.[54]
Ircinia strobilina
(E24-2)
(E52)		No
SpongiidaeSpongia tubulifera
(E11-2)		No
HaploscleridaCallyspongiidaeCallyspongia longissima
(E28)		No
Callyspongia plicifera
(E31)		No
Callyspongia vaginalis
(E16)		No
ChalinidaeHaliclona (Rhizoniera) curacaoensis
(EY18-4)		No
NiphatidaeAmphimedon compressa
(E29)		8,8′-dienecyclostellettamine is active against C. albicans and A. fumigatus.[23,24]
Niphates digitalis
(E15)		No
Niphates erecta
(E49)
(MA18-7)
(MA18-12)		No
PetrosiidaeXestospongia muta
(EP)		Xestospongiamide is active against A. niger and C. albicans.
Xestospongin C and D are active against fluconazole-resistant Candida spp. 		[55,56,57]
HomosclerophoridaPlakinidaePlakinastrella onkodes
(E3)		Plakinic acid F is active against C. albicans and A. fumigatus.
Epiplakinic acid F is active against C. albicans and A. fumigatus.
1,2-dioxane ring peroxide acid is active against C. albicans and A. fumigatus.
Plakortide F is active against C. albicans.
1,2-dioxolane perocide acid is active against C. albicans.		[58,59,60,61]
PoeciloscleridaCrambeidaeMonanchora arbuscula
(E35)		Dehydrobatzelladine C is active against C. albicans and A. fumigatus.
Batzelladine L shows activity against A. flavus.
Mirabilin B is active against C. neoformans.		[61,62,63,64]
MicrocionidaeClathria gomezae
(EY18-11)		No
Clathria (Thalysisas) virgultosa
(E7-E34)		No
MycalidaeMycale laevis
(MA18-1)
(MA18-5)		No
ScopalinidaScopalinidaeScopalina ruetzleri
(DNY)
(E53)
(EY18-7)		Extract showed activity against C. albicans.[26]
SuberitidaHalichondriidaeHalichondria melanadocia
(E18-M1)		No
SubertidaeAaptos sp.
(E38)		3-(phenethylamino)demethyl(oxy)aaptamine is active against C. albicans, C. parapsilosis, Trichophyton rubrum and Microsporum gypseum.[65,66,67]
TethyidaTethyidaeTethya sp.
(E20)		Extract from species of this genus showed mild activity against C. albicans.[68,69]
TetractinellidaGeodiidaeMelophlus hajdui
(E4)		No
TetillidaeCinachyrella kuekenthali
(MA18-2)		No
VerongiidaAplysinidaeAiolochroia crassa
(E50)
(MA18-4)		No
Aplysina cauliformis
(E36)		No
Aplysina fistularis
(E46)		Lovastatin is active against Candida, Aspergillus, Fusarium and Trichophyton species.[70]
Aplysina fulva
(E42)
(EY18-5)		Lectin is active against C. albicans and C. tropicalis.[71,72,73]
Aplysina muricyana
(E47)		No
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Pech-Puch, D.; Grilo, D.; Calva-Pérez, S.E.; Pedras, A.; Villegas-Hernández, H.; Guillén-Hernández, S.; Díaz-Gamboa, R.; Tunjano, M.F.; Rodríguez, J.; Lenis-Rojas, O.A.; et al. Antifungal Potential of Marine Organisms of the Yucatan Peninsula (Mexico) against Medically Important Candida spp. Molecules 2023, 28, 606. https://doi.org/10.3390/molecules28020606

AMA Style

Pech-Puch D, Grilo D, Calva-Pérez SE, Pedras A, Villegas-Hernández H, Guillén-Hernández S, Díaz-Gamboa R, Tunjano MF, Rodríguez J, Lenis-Rojas OA, et al. Antifungal Potential of Marine Organisms of the Yucatan Peninsula (Mexico) against Medically Important Candida spp. Molecules. 2023; 28(2):606. https://doi.org/10.3390/molecules28020606

Chicago/Turabian Style

Pech-Puch, Dawrin, Diana Grilo, Susana Eunice Calva-Pérez, Andreia Pedras, Harold Villegas-Hernández, Sergio Guillén-Hernández, Raúl Díaz-Gamboa, Mateo Forero Tunjano, Jaime Rodríguez, Oscar A. Lenis-Rojas, and et al. 2023. "Antifungal Potential of Marine Organisms of the Yucatan Peninsula (Mexico) against Medically Important Candida spp." Molecules 28, no. 2: 606. https://doi.org/10.3390/molecules28020606

APA Style

Pech-Puch, D., Grilo, D., Calva-Pérez, S. E., Pedras, A., Villegas-Hernández, H., Guillén-Hernández, S., Díaz-Gamboa, R., Tunjano, M. F., Rodríguez, J., Lenis-Rojas, O. A., Jiménez, C., & Pimentel, C. (2023). Antifungal Potential of Marine Organisms of the Yucatan Peninsula (Mexico) against Medically Important Candida spp. Molecules, 28(2), 606. https://doi.org/10.3390/molecules28020606

Article Metrics

Back to TopTop